Entry Point Capital, LLC Takeda Pharmaceutical CO LTD Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
A detailed history of Entry Point Capital, LLC transactions in Takeda Pharmaceutical CO LTD stock. As of the latest transaction made, Entry Point Capital, LLC holds 13,971 shares of TAK stock, worth $191,961. This represents 0.08% of its overall portfolio holdings.
Number of Shares
13,971
Previous 15,804
11.6%
Holding current value
$191,961
Previous $224,000
17.86%
% of portfolio
0.08%
Previous 0.13%
Shares
2 transactions
Others Institutions Holding TAK
# of Institutions
338Shares Held
68.6MCall Options Held
1.72MPut Options Held
178K-
Capital Research Global Investors Los Angeles, CA13.2MShares$181 Million0.04% of portfolio
-
Morgan Stanley New York, NY5.6MShares$77 Million0.01% of portfolio
-
Goldman Sachs Group Inc New York, NY4.63MShares$63.6 Million0.01% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA4.22MShares$57.9 Million0.05% of portfolio
-
First Trust Advisors LP Wheaton, IL3.24MShares$44.5 Million0.04% of portfolio
About TAKEDA PHARMACEUTICAL CO LTD
- Ticker TAK
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 3,109,050,112
- Market Cap $42.7B
- Description
- Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived t...